Patients with a higher TMB are more likely to respond to ICI in various settings, including PD-(L)1 blockade in NSCLC [10], CTLA-4 blockade in malignant melanoma [11], and combined PD(L)-1 and CTLA-4 blockade in NSCLC [17]. This evidence concerns the gene CD274 and melanoma.